Patents by Inventor Brian P. Ward

Brian P. Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptide inhibitors of HSP27 kinase and uses therfor
    Patent number: 9649354
    Abstract: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 16, 2017
    Assignee: Purdue Research Foundation
    Inventors: Alyssa Panitch, Brandon Seal, Brian P. Ward
  • POLYPEPTIDE INHIBITORS OF HSP27 KINASE AND USES THERFOR
    Publication number: 20170072009
    Abstract: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 16, 2017
    Inventors: Alyssa Panitch, Brandon Seal, Brian P. Ward
  • Glucagon analogs exhibiting GIP receptor activity
    Patent number: 9587005
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: March 7, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Brian P. Ward
  • Glucagon Analogs Exhibiting GIP Receptor Activity
    Publication number: 20160115215
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 28, 2016
    Inventors: Richard D. Dimarchi, Brian P. Ward
  • Glucagon analogs exhibiting GIP receptor activity
    Patent number: 9249206
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: February 2, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Brian P. Ward
  • Glucagon Analogs Exhibiting GIP Receptor Activity
    Publication number: 20150259393
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: March 23, 2015
    Publication date: September 17, 2015
    Inventors: Richard D. DiMARCHI, Brian P. WARD
  • Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
    Publication number: 20140112947
    Abstract: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.
    Type: Application
    Filed: July 3, 2013
    Publication date: April 24, 2014
    Inventors: Alyssa Panitch, Brandon Seal, Brian P. Ward
  • Glucagon analogs exhibiting GIP receptor activity
    Patent number: 8507428
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: August 13, 2013
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Brian P. Ward
  • GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY
    Publication number: 20120238493
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: December 20, 2011
    Publication date: September 20, 2012
    Inventors: Richard D. DiMARCHI, Brian P. WARD
  • GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS
    Publication number: 20120172295
    Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
    Type: Application
    Filed: June 16, 2010
    Publication date: July 5, 2012
    Applicant: Indiana University Research And Technology Corp
    Inventors: Richard D. Dimarchi, David L. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day, James Patterson, Brian P. Ward, Tao Ma